Zimbuck – Your Market. Your Community.
BREAKING: Johnson & Johnson (JNJ) has agreed to acquire Ollin Biosciences for $2.2 billion upfront, adding a late-stage eye-drug candidate to its ophthalmology pipeline.

Ollin's lead program OLN324 is a Phase 3 bispecific antibody targeting VEGF and Ang2 for wet age-related macular degeneration and diabetic macular edema. Ollin shareholders can receive up to about $1.125 billion more in regulatory and commercial milestone payments, and Blackstone Life Sciences will fund the Phase 3 program. The deal is expected to close before the end of 2026, subject to regulatory approvals.

#JohnsonAndJohnson #JNJ #Biotech #Pharma #Stocks #Investing
Like
Love
3
77 Views